Abstract: There are 5 major sets of diagnosis criteria for BD: Mason & Barnes, O'Duffy, Dilsen, Japan revised criteria, and the International criteria (the latest one). To evaluate their accuracy we analysed their sensitivity and specificity in 2069 BD and 1519 control patients. The accuracy was calculated by the sum of BD patients fulfilling the criteria and the control patients correctly classified as non BD, divided by the sum of the ...
Classification tree for the diagnosis of Behcet's disease (BD).
Abstract: The diagnosis method by Classification And Regression Tree (CART) is gaining more importance every year, specially in Rheumatology by the efforts of the American College of Rheumatology. The classification tree not only provides an accurate tool for diagnosis, it gives a better insight of the manifestations of the disease and the value of different criteria for the diagnosis. In this study we analyzed 1992 Behcet's patients (BP) and 1506 control ...
OPHTHALMOLOGIC SIDE EFFECTS OF CHLOROQUINE, ANALYSIS IN 1598 PATIENTS WITH RHEUMATlC DISEASES.
Abstract: Antimalarials are among the most important disease modifying drugs used in Rheumatology. The major problem with them is their effects on eyes. We have done a retrospective study on 1598 patients with RA and SLE using Chloroquine for 1 month to 16 years (Mean 41 months). Eye problems was detected in 330 patients (20.6%). We found corneal deposition in 205 (13%) that was graded as severe (11%), moderate (12%) and ...
Clinical manifestations of Behcet's disease in Iran. Analysis of 2068 cases.
Abstract: The annual incidence of Behcet's Disease (BD) is as high as 300 patients per year. The mean age at the onset of the first symptom is 26.7 years (SD = 9.7). The sex distribution is 54% male and 46% female. The initial manifestation was mainly oral aphthosis (73%), uveitis (13%), genital ulcerations (11%), arthritis (9%), and skin manifestations (9%). Clinical manifestations were as fallow: mucous membrane manifestations were seen in 95.5% ...
OUTCOME of PULSE CYCLOPHOSPHAMIDE (PCP) in TYPE IV SLE NEPHRITIS WITHOUT RENAL FAILURE.
Abstract: Results of PCP are well known in lupus nephritis. We present here it's outcome in patients with early stage of WH0 type IV lupus nephritis. The criteria for selection was a serum creatinine inferior to 1.3 mg/ 100 ml and a minimum follow up time of 18 months. 35 patients fulfilled the selection criteria. proteinuria, hematuria, leucocyturia, cast, BUN, creatinine, and blood pressure were measured before PCP and after each one. ...
Lupus Nephritis in Iran. Analysis of 287 cases.
Abstract: Systemic Lupus Erythematosus (SLE) is a rather frequent disease in Iran. In the past 13 years, 449 patients with SLE attended the SLE clinic. Lupus nephritis was discovered in 278 of them. The purpose of this study is to demonstrate the caracteristics of lupus nephritis in Iran (percentage of proteinuria, hematuria, leucocyturia, casts, renal insufficiency, hypertension, and patterns of renal biopsy), to compare them to the remaining patients with SLE ...
Iran Behcet's Disease Dynamic Activity Measure (IBDDAM).
Abstract: The evaluation of the inflammatory state of Behcet`s Disease and it's quantification is most difficult. The difficulty is due to the recurrent attacks and spontaneous remissions that characterizes the disease. In IBDDAM the patients is evaluated on several weeks or months. Each attack is measured separately and given an index. The obtained indexes are added together and the total is divided by the number of months of the evaluation period. ...
Pulse cyclophosphamide in SLE nephritis, analysis of 84 cases.
Abstract: Pulse cyclophosphamide (PCP) is a well established method for the treatment of lupus nephritis. PCP seems to produce better results with lesser side effects, than oral cytotoxic drugs. We presenthere, our experience with this method, in 84 patients. All patients had a WHO type IV histological lesion, on light microscopy, Proteinuria, hematuria, leucocyturia, casts, BUN, creatinine, and blood pressure were measured before starting PCP and after each one. The first ...
Pulse cyclophosphamide in Lupus Nephritis.
Abstract: The prognosis of Lupus Nephritis has dramatically changed since the introduction of cytotoxic drugs in their treatment. Different protocols have been proposed to reach this goal. Pulse cyclophosphamide (PCP) was first introduced in the treatment of Systemic Lupus Erythematosus by Sessoms & Kovarsky in 1984. Austin and Colleagues demonstrated it's superiority upon other regimens in Lupus Nephritis in 1986. Pulse Cyclophosphamide is now a well established method for the treatment ...
Long-term outcome of cyclophosphamide I.V. bolus in Behcet's disease ocular lesions.
Abstract: Since our first report in 1987 to the XIth EULAR Congress of Rheumatology several reports had proved the efficacy of pulsed cyclophosphamide (PCP) in severe posterior uveitis (PU) and retinal vasculitis (RV) of Behcet's Disease (BD). The aim of this report is to show the outcome of 45 patients who have been followed for more than 2 years. PCP was administered as lg/m2/body surface, once per month, with 0.5 mg ...